New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Novavax, Inc.

NVAX

Healthcare Biotechnology

Novavax, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.1 billion, up 64.7% from fiscal 2024.

Revenue
−3.05%
EPS
n/m
Free cash flow
n/m
Total debt
+19.3%

Quarter to September 2026, against a year earlier

7.76 0.03 +0.39%
Market cap
$1.3B
P/E
n/m
Fwd P/E FY26e
n/m
Dividend yield
—
F-score
5/9
ROIC
0.00%
Net debt / EBITDA
−1.0×
Payout ratio
—

Ratios over time FY16 to FY25

Returns on capital

ROIC was 0.00% in FY25, the highest of these ten years.

ROEROIC
FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
ROE−195.0%342.6%137.0%75.0%−189.6%−1265.7%133.5%80.7%28.0%−117.2%
ROIC−373.8%−351.9%−225.2%−142.7%−141.2%0.0%0.0%0.0%0.0%0.0%

Debt

It holds more cash than debt: net debt is −1.04× a year’s EBITDA.

Net debt / EBITDA
FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Net debt / EBITDA−0.2×−0.8×−1.3×−2.1×1.1×0.7×1.9×0.7×3.5×−1.0×

Cash cycle, in days

Customers pay in 35 days, inventory is held 58 days and suppliers are paid in 123. Suppliers fund 31 days of working capital.

Cash cycleDays to pay suppliersDays to be paid
FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Cash cycle000147201−3173−5814−1−31
Days to pay suppliers0000035678814175123
Days to be paid000147201145151105835

Per share, from FY16

Since FY16, per share: revenue has grown 22.3% a year.

Revenue
FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Revenue1.0×1.9×1.6×0.7×7.3×13.6×22.4×8.6×4.0×6.1×
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
P/E ratio
2.45 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Piotroski F-Score
5 4 3 4 4 4 2 1 3 2
P/S ratio
0.97 1.79 0.63 0.39 9.29 13.49 5.14 19.84 12.20 22.40
Altman Z-Score
(2.18) (4.27) (4.46) (2.95) (1.61) 2.31 (13.13) (9.83) (5.87) (4.33)
P/FCF ratio
0.00 13.48 0.00 0.00 39.65 0.00 0.00 0.00 0.00 0.00
Altman Z″-Score (non-manufacturers)
(7.28) (11.94) (12.95) (10.52) (9.70) (2.17) (29.51) (24.13) (13.28) (8.61)
Beneish M-Score
0.39 (3.56) 3.32 (2.58) (5.61) 19.99 — — — (5.91)
P/Operating CF
(27.58) (7.07) (3.53) (6.50) (31.09) (49.92) (4.04) (15.03) (8.77) (5.33)
P/B ratio
0.00 0.00 0.00 0.00 0.00 10.23 0.00 0.00 0.00 0.00
EV/Sales
0.52 0.75 0.27 (0.19) 8.24 12.56 17.94 26.15 16.44 25.69
EV/EBITDA
1.23 0.00 0.00 0.62 0.00 0.00 0.00 0.00 0.00 0.00
EV/FCF
(2.34) 5.66 (0.35) 0.75 35.17 (61.59) (2.79) (4.82) (3.45) (1.42)
Current Ratio
2.13 0.98 0.70 0.69 0.90 2.15 3.77 2.62 2.76 4.33
Net Debt/EBITDA
(1.04) 3.54 0.68 1.87 0.72 1.08 (2.08) (1.32) (0.82) (0.19)
Debt/Equity
(1.93) (0.36) (0.31) (0.31) (0.92) 0.58 (1.72) (1.90) (3.12) (57.04)
ROE
(117.16%) 27.97% 80.69% 133.49% (1,265.71%) (189.60%) 74.98% 137.02% 342.60% (195.01%)
ROA
32.17% (11.17%) (26.88%) (27.21%) (83.85%) (47.65%) (69.67%) (72.38%) (52.75%) (71.75%)
ROIC
0.00% 0.00% 0.00% 0.00% 0.00% (141.24%) (142.67%) (225.18%) (351.93%) (373.77%)
Return on Tangible Assets
78.19% (166.02%) 293.87% 142.32% 18,434.83% (49.29%) (160.07%) (180.84%) (110.96%) (107.02%)
Average Days of Receivables
34.58 57.94 110.29 15.17 144.88 201.08 146.69 0.00 0.00 0.00
Earnings Yield
40.77% (15.30%) (108.49%) (84.78%) (16.28%) (6.09%) (144.72%) (27.72%) (48.46%) (81.10%)
Free Cash Flow Yield
(23.15%) 7.42% (123.77%) (66.90%) 2.52% (1.51%) (125.26%) (27.37%) (39.08%) (80.53%)
Free Cash Flow per Share
(1.55) 0.60 (7.67) (6.51) 3.57 (1.69) (4.99) (10.07) (10.16) (20.46)
Book value per Share
(0.79) (4.10) (7.11) (8.11) (4.73) 10.90 (7.72) (9.08) (6.95) (0.41)
Free Cash Flow
(251.02) 90.74 (772.77) (508.92) 265.46 (97.16) (120.15) (186.20) (148.66) (276.97)
EV/EBIT
1.30 0.00 0.00 0.60 0.00 0.00 0.00 0.00 0.00 0.00
Other line items

Show all line items

Columns are period end dates · fundamentals updated Nov 18, 2026